

- 99 -

CLAIMS

1. An experimental animal having implanted therein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene, said animal being a non-human animal in which a hypercoagulable state persists for a long period of time.

2. The animal according to claim 1 wherein said part of human tissue factor lacks the intracellular region.

3. The animal according to claim 1 or 2 wherein said animal cell is a mammalian cell.

4. The animal according to claim 3 wherein said mammalian cell is a human myeloma cell.

5. The animal according to any one of claims 1 to 4 wherein said animal is a mouse.

6. The animal according to any of claims 1 to 5 wherein said hypercoagulable state is indicated by at least one of the phenomena comprising an increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex.

7. A method of generating the animal according to any one of claims 1 to 6, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected.

8. A method of screening an anti-thrombotic agent which method comprises using the animal according to any one of claims 1 to 6.

9. A preventive or therapeutic agent for diseases having a persistent hypercoagulable state, said agent comprising an antibody to human tissue factor (human TF).

- 100 -

10. The preventive or therapeutic agent according to claim 9 wherein said antibody is a polyclonal antibody.

5 11. The preventive or therapeutic agent according to claim 9 wherein said antibody is a monoclonal antibody.

Sub A3 → 12. The preventive or therapeutic agent according to claim 9 or 11 wherein said antibody is a recombinant antibody.

10 13. The preventive or therapeutic agent according to claim 9 or 12 wherein said antibody is an altered antibody.

15 14. The preventive or therapeutic agent according to claim 9, 12, or 13 wherein said altered antibody is a chimeric antibody or a humanized antibody.

15 15. The preventive or therapeutic agent according to claim 14 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

Sub A4 → 20 16. The preventive or therapeutic agent according to claim 9 or any one of claims 12-15 wherein said antibody is a modified antibody.

25 17. The preventive or therapeutic agent according to claim 16 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

18. A preventive or therapeutic agent for a hypercoagulable state resulting from infections, said agent comprising an antibody against human tissue factor (human TF).

30 19. The preventive or therapeutic agent according to claim 18 wherein said antibody is a polyclonal antibody.

35 20. The preventive or therapeutic agent according to claim 18 wherein said antibody is a monoclonal antibody.

Sub A5 → 21. The preventive or therapeutic agent according to claim 18 or 20 wherein said antibody is a recombinant

antibody.

22. The preventive or therapeutic agent according to claim 18 or 21 wherein said antibody is an altered antibody.

5 23. The preventive or therapeutic agent according to claim 18, 21, or 22 wherein said altered antibody is a chimeric antibody or a humanized antibody.

24. The preventive or therapeutic agent according to claim 23 wherein said humanized antibody is a
10 humanized antibody of version b-b, i-b, or i-b2.

25. The preventive or therapeutic agent according to claim 18 or any one of claims 21-24 wherein said antibody is a modified antibody.

26. The preventive or therapeutic agent according to claim 25 wherein said modified antibody is an antibody
15 fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

27. A preventive or therapeutic agent for venous thrombosis, said agent comprising an antibody to human
20 tissue factor (human TF).

28. The preventive or therapeutic agent according to claim 27 wherein said antibody is a polyclonal antibody.

29. The preventive or therapeutic agent according to claim 27 wherein said antibody is a monoclonal
25 antibody.

See 6 30. The preventive or therapeutic agent according to claim 27 or 29 wherein said antibody is a recombinant antibody.

30 31. The preventive or therapeutic agent according to claim 27 or 30 wherein said antibody is an altered antibody.

32. The preventive or therapeutic agent according to claim 27, 30, or 31 wherein said altered antibody is a
35 chimeric antibody or a humanized antibody.

33. The preventive or therapeutic agent according to claim 32 wherein said humanized antibody is a

humanized antibody of version b-b, i-b, or i-b2.

Sub 97 → 34. The preventive or therapeutic agent according to claim 27 or any one of claims 30-33 wherein said antibody is a modified antibody.

5 35. The preventive or therapeutic agent according to claim 34 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

10 36. A preventive or therapeutic agent for arterial thrombosis, said agent comprising an antibody to human tissue factor (human TF).

37. The preventive or therapeutic agent according to claim 36 wherein said antibody is a polyclonal antibody.

15 38. The preventive or therapeutic agent according to claim 36 wherein said antibody is a monoclonal antibody.

Sub 98 → 20 39. The preventive or therapeutic agent according to claim 36 or 38 wherein said antibody is a recombinant antibody.

40. The preventive or therapeutic agent according to claim 36 or 39 wherein said antibody is an altered antibody.

25 41. The preventive or therapeutic agent according to claim 36, 39, or 40 wherein said altered antibody is a chimeric antibody or a humanized antibody.

42. The preventive or therapeutic agent according to claim 41 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

30 Sub 99 → 43. The preventive or therapeutic agent according to claim 36 or any one of claims 39-42 wherein said antibody is a modified antibody.

35 44. The preventive or therapeutic agent according to claim 43 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

45. A preventive or therapeutic agent for diseases

- 103 -

resulting from the medial thickening of the vessels, said agent comprising an antibody to human tissue factor (human TF).

5 46. The preventive or therapeutic agent according to claim 45 wherein said antibody is a polyclonal antibody.

 47. The preventive or therapeutic agent according to claim 45 wherein said antibody is a monoclonal antibody.

10 48. The preventive or therapeutic agent according to claim 45 or 47 wherein said antibody is a recombinant antibody.

Sub 10 → 15 49. The preventive or therapeutic agent according to claim 45 or 48 wherein said antibody is an altered antibody.

 50. The preventive or therapeutic agent according to claim 45, 48, or 49 wherein said altered antibody is a chimeric antibody or a humanized antibody.

20 51. The preventive or therapeutic agent according to claim 50 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

Sub 11 → 25 52. The preventive or therapeutic agent according to claim 43 or any one of claims 48-51 wherein said antibody is a modified antibody.

 53. The preventive or therapeutic agent according to claim 52 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).